{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10.0"}]}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"0.8"}]}],"title":"Blood creatinine phosphokinase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3.3"}]}],"title":"White blood cell count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4.2"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"0"}]}],"title":"Appendicitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8.3"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.5"}]}],"title":"Asthenia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"120"}],"units":"Participants"}],"description":"An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events.","groups":[{"description":"Participants received 600 mg oral alectinib twice daily (BID) for 2 years","id":"OG000","title":"Alectinib"},{"description":"Participants received platinum-based chemotherapy for 4 cycles (cycle length = 21 days).","id":"OG001","title":"Platinum-Based Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The safety-evaluable population consisted of all participants who received at least one dose of study treatment, with participants assigned to treatment groups according to the treatment received. All participants who received any dose of alectinib are included in the alectinib treatment arm.","reportingStatus":"POSTED","timeFrame":"Until 28 days after the last dose of alectinib (up to 2 years) or 28 days after end of last cycle of chemotherapy (up to 4 cycles)","title":"AEs Grade 3-5 With a Difference in Incidence Rate of at Least 2% Between Treatment Arms","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}